

Pfizer International Symposium on Intensive Care and Emergency Medicine (ISICEM) 2022 hybrid symposium

Tuesday 22 March, 2022
12:30–13:30 (CET)
Gold Hall, SQUARE – Brussels Convention Centre



Managing the risks and challenges of IMD in the ICU

This symposium will explore the current updates, challenges and emerging risk factors of invasive mould disease (IMD) in the intensive care unit (ICU). Emphasis will be given to viral-associated IMD in critically ill patients in the ICU and the value of high-suspicion–low-threshold for action for IMD management. The role of antifungal therapy in treating ICU patients with confounding factors and comorbidities will be investigated, using a real-life patient case study which will incorporate several aspects of early suspicion, diagnosis and treatment options.

Agenda

Chair: **Joost Wauters (Belgium)**

-
- 12:30–12:35 CET » Welcome and introduction**
Joost Wauters (Belgium)
-
- 12:35–12:50 CET » Highlighting the challenges of diagnosing IMD in the ICU:
A real-life case study**
Daniele Roberto Giacobbe (Italy)
-
- 12:50–13:05 CET » Managing the risks associated with viral-associated IMD**
Paul Verweij (Netherlands)
-
- 13:05–13:20 CET » Therapeutic strategies for critically ill patients with IMD in the ICU**
Joost Wauters (Belgium)
-
- 13:20–13:30 CET » Discussion, Q&A, summary and closing remarks**
All faculty
-



Pfizer NV, Pleinlaan 17, 1050 Ixelles
Tel: +32 2 554 62 11, www.pfizer.be

Prescribing information is available upon request

220224; Date of Preparation: February 2022
© 2022 Pfizer Inc. All rights reserved.